<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>作為您在 Google 上的首選新聞來源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>日本製藥公司大冢製藥（Daiichi Sankyo Co. Ltd.，DSKYF,4568.T, DSNKY）週一報告稱，截至 2026 年 3 月 31 日的財年淨收入較上年下降。</p>
<p>2026 財年，歸屬於公司所有者的利潤下降 12.1%，從前一年的 2957.6 億日元降至 2598.7 億日元。</p>
<p>每股收益為 140.37 日元，而去年為 155.87 日元。</p>
<p>核心營業利潤從前一年的 3128.4 億日元躍升至 359 億日元。</p>
<p>營業利潤從去年同期的 3319.3 億日元下降 31%，降至 2290.9 億日元。</p>
<p>收入從前一年的 1890 億日元增加至 2120 億日元。</p>
<p>展望未來，公司預計 2027 財年收入為 2280 億日元，核心營業利潤為 360 億日元，而營業利潤預計為 315 億日元。</p>
<p>對於 2027 財年，公司預計歸屬於公司所有者的利潤為 2600 億日元，基本每股收益為 142.88 日元。</p>
<p>大冢製藥在東京證券交易所收盤上漲 2.04%，報 2649 日元。</p>
<p>如有意見和反饋，請聯繫：editorial@rttnews.com</p>
<p>商業新聞</p>

4568

<p>第一三共株式會社報告截至 2026 年 3 月 31 日的財年淨收入下降 12.1%，歸屬於股東的利潤為 2598.7 億日元。每股收益降至 140.37 日元。儘管收入增加至 2.12 萬億日元，營業利潤卻下降 31%，降至 2290.9 億日元。對於 2027 財年，公司預計收入為 2.28 萬億日元，利潤為 2600 億日元，每股收益預計為 142.88 日元。該股在東京證券交易所上漲 2.04%，報 2649 日元</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>作為您在 Google 上的首選新聞來源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Daiichi Sankyo Co. Ltd. (DSKYF,4568.T, DSNKY), a Japanese pharmaceutical company, on Monday reported lower net income in the full year ended March 31, 2026 compared with the previous year.</p>
<div class="lb-trans"><p>日本製藥公司大冢製藥（Daiichi Sankyo Co. Ltd.，DSKYF,4568.T, DSNKY）週一報告稱，截至 2026 年 3 月 31 日的財年淨收入較上年下降。</p>
</div><p>For the full year 2026, profit attributable to the owners of the company declined 12.1 percent to 259.87 billion from 295.76 billion in the prior year.</p>
<div class="lb-trans"><p>2026 財年，歸屬於公司所有者的利潤下降 12.1%，從前一年的 2957.6 億日元降至 2598.7 億日元。</p>
</div><p>Earnings per share were 140.37 yen versus 155.87 last year.</p>
<div class="lb-trans"><p>每股收益為 140.37 日元，而去年為 155.87 日元。</p>
</div><p>Core operating profit jumped to 3.59 billion yen from 312.84 billion yen in the prior year.</p>
<div class="lb-trans"><p>核心營業利潤從前一年的 3128.4 億日元躍升至 359 億日元。</p>
</div><p>Operating profit declined 31 percent to 229.09 billion yen from 331.93 billion in the same period last year.</p>
<div class="lb-trans"><p>營業利潤從去年同期的 3319.3 億日元下降 31%，降至 2290.9 億日元。</p>
</div><p>Revenue increased to 2.12 trillion yen from 1.89 trillion yen in the previous year.</p>
<div class="lb-trans"><p>收入從前一年的 1890 億日元增加至 2120 億日元。</p>
</div><p>Looking ahead, the company expects revenue of 2.28 trillion yen and core operating profit of 360 billion yen, while operating profit is expected to be 315 billion yen for the full year ending March 31, 2027.</p>
<div class="lb-trans"><p>展望未來，公司預計 2027 財年收入為 2280 億日元，核心營業利潤為 360 億日元，而營業利潤預計為 315 億日元。</p>
</div><p>For the full year 2027, the company expects profit attributable to the owners of the company to be 260 billion yen with basic earnings per share of 142.88.</p>
<div class="lb-trans"><p>對於 2027 財年，公司預計歸屬於公司所有者的利潤為 2600 億日元，基本每股收益為 142.88 日元。</p>
</div><p>Daiichi Sankyo closed trading 2.04% higher at JPY 2,649 on the Tokyo Stock Exchange.</p>
<div class="lb-trans"><p>大冢製藥在東京證券交易所收盤上漲 2.04%，報 2649 日元。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意見和反饋，請聯繫：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商業新聞</p>
</div>

第一三共收益下降；發佈 2027 財年指引